Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 7.50 |
| Open | 7.40 |
| Bid | 7.28 x 0 |
| Ask | 7.35 x 0 |
| Day's Range | 7.30 - 7.40 |
| 52 Week Range | 3.13 - 8.49 |
| Volume | 7,434 |
| Avg. Volume | 9,339 |
| Market Cap | 93.478M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | 22.81 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Simply Wall St.
If You Had Bought BioSyent (CVE:RX) Stock A Year Ago, You Could Pocket A 58% Gain Today
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...
- Simply Wall St.
BioSyent Inc.'s (CVE:RX) Stock Has Fared Decently: Is the Market Following Strong Financials?
Most readers would already know that BioSyent's (CVE:RX) stock increased by 6.5% over the past three months. Given its...
- Simply Wall St.
BioSyent Inc. Just Missed Earnings - But Analysts Have Updated Their Models
BioSyent Inc. (CVE:RX) came out with its quarterly results last week, and we wanted to see how the business is...
© 2021 Verizon Media. All rights reserved.
